Transforming growth factor beta (TGF-ß) pathway activation by IPF fibroblast-derived soluble factors is mediated by IL-6 trans-signaling

Shochet, Gali Epstein; Bardenstein-Wald, Becky; Brook, Elizabetha; Shitrit, David

doi:10.1183/13993003.congress-2020.3352

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Excessive deposition of ECM and its stiffening lower the threshold for TGF-β1 activation thereby creating a self-amplifying loop that promotes the expansion of myofibroblasts and fibrosis development [56]. These processes may be enhanced by factors such as interleukin (IL)-6, IL-1β, or TNF-α, which potentiate TGF-β1 expression and activation of the TGF-β1 signaling pathway [57,58]. All these changes are aggravated by the resistance of IPF (myo)fibroblasts to apoptosis [59].…”

Section: Idiopathic Pulmonary Fibrosismentioning

confidence: 99%

EGFR Signaling in Lung Fibrosis

Schramm

Schaefer

Wygrecka

2022

Cells

View full text Add to dashboard Cite

In this review article, we will first provide a brief overview of the ErbB receptor–ligand system and its importance in developmental and physiological processes. We will then review the literature regarding the role of ErbB receptors and their ligands in the maladaptive remodeling of lung tissue, with special emphasis on idiopathic pulmonary fibrosis (IPF). Here we will focus on the pathways and cellular processes contributing to epithelial–mesenchymal miscommunication seen in this pathology. We will also provide an overview of the in vivo studies addressing the efficacy of different ErbB signaling inhibitors in experimental models of lung injury and highlight how such studies may contribute to our understanding of ErbB biology in the lung. Finally, we will discuss what we learned from clinical applications of the ErbB1 signaling inhibitors in cancer in order to advance clinical trials in IPF.

show abstract

Section: Idiopathic Pulmonary Fibrosismentioning

confidence: 99%